Similarly, mutations in epigenetic modifiers (DNMT3A, TET2, or ASXL1) or spliceosome genes (U2AF1, SF3B1, SRSF2, or ZRSR2) are relatively uncommon in TP53-mutated myeloid malignancies in this cohort, with a cumulative frequency of 14.3% and 4.8%, respectively. This evidence concerns the gene ZRSR2 and myeloid neoplasm.